Apimeds Faces Governance Shake-Up and Strategic Shift

Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has shared an announcement.

On March 20, 2026, majority stockholders of Apimeds Pharmaceuticals US, Inc., led by Apimeds Korea and Inscobee, removed four directors by written consent amid concerns over MindWave Innovations’ asserted ownership of digital assets and the company’s merger process, then installed three new directors, including Youngjik Cho as chair and chief executive, and dismissed CEO Vin Menon and CFO Erick Frim. The same day, the reconstituted board amended bylaws to give majority shareholders power to fill board vacancies and approve bylaw changes, approved a strategic expansion into Korean cosmetics, K-culture photo booth and e-commerce ventures through non-binding joint venture MOUs with Assemble, Hilluck and LK Ventures, delayed a planned 1-for-10 reverse stock split announced on March 16, 2026, and signaled it would contest MindWave’s March 24, 2026 challenge to the shareholder coup, setting up a potential governance and litigation battle that could reshape the company’s strategic direction and capital-market posture.

The governance shake-up at Apimeds Pharmaceuticals US, Inc. on March 20, 2026 was initiated after majority stockholders said documentation failed to resolve doubts about MindWave’s digital-asset representations in the merger. In response, they removed four directors, appointed Youngjik Cho, Minguk Ji and Junyoung Yu to the board, and immediately ousted CEO Vin Menon and CFO Erick Frim, consolidating control with a new leadership team.

Following these changes, the newly constituted board revised the company’s bylaws so that holders of a majority of voting power can fill board vacancies and approve future bylaw amendments. These amendments enhance majority shareholders’ influence over corporate governance at a time of heightened scrutiny of the MindWave transaction and related support and lock-up agreements.

Operationally, the board authorized a diversification strategy labeled a business expansion, pursuing joint ventures with Assemble Corporation and Hilluck Co. to distribute Korean cosmetics in North America. It also backed an MOU with LK Ventures to bring the “Life4Cuts” K-culture experiential photo booth platform and associated direct-to-consumer e-commerce model to North America, though all three MOUs remain subject to definitive agreements.

On the capital-structure front, Apimeds decided to delay a previously announced amendment to its charter that was intended to implement a 1-for-10 reverse stock split around March 26, 2026. The board said it will continue to evaluate the timing and advisability of the reverse split, leaving investors uncertain about the near-term trajectory of the company’s share consolidation plans.

Tensions escalated further on March 24, 2026, when MindWave issued a press release, purportedly on the company’s behalf and without the new board’s authorization, disputing the validity of the written-consent actions and alleging a breach of a support and lock-up agreement. Apimeds, Apimeds Korea and Inscobee rejected those claims and indicated they would vigorously defend the legitimacy of the shareholder-driven overhaul if former officers and directors pursue litigation, raising the prospect of a protracted governance dispute that could affect the company’s strategic and operational stability.

More about Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. operates in the healthcare and pharmaceuticals sector and is linked to Korean shareholders Apimeds Korea and Inscobee. The company has historically focused on its core pharma business but is now positioning itself to diversify into consumer-facing segments such as Korean cosmetics, K-culture experiential services and e-commerce, particularly targeting the North American market through partnerships with Korean firms.

Average Trading Volume: 160,415

Technical Sentiment Signal: Strong Sell

Current Market Cap: $21.5M

Find detailed analytics on APUS stock on TipRanks’ Stock Analysis page.